PROCEPT BioRobotics Under Investigation for Securities Fraud Claims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy PRCT?
Source: Newsfilter
- Investigation Background: Ademi LLP is investigating potential securities fraud claims against PROCEPT BioRobotics due to possibly inaccurate statements regarding its financial statements, business operations, and prospects, which could lead to investor losses.
- Sales Disclosure Issues: The investigation focuses on whether PROCEPT BioRobotics' disclosures regarding the sales processes and inventory of its disposable handpieces were accurate, particularly as these sales relied on quarter-end promotional discounts that have since been discontinued.
- Financial Forecast Downgrade: As a result of the reliance on discontinued promotional discounts, PROCEPT BioRobotics reported quarterly revenue 19% below forecasts, and its annual sales guidance for 2026 is also 5% below expectations, potentially undermining market confidence in the company.
- Potential Legal Consequences: This investigation could lead to securities fraud litigation, and if wrongdoing is confirmed, it may severely impact the company's stock price and reputation, prompting investors to closely monitor further developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRCT
Wall Street analysts forecast PRCT stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 22.690
Low
38.00
Averages
51.75
High
65.00
Current: 22.690
Low
38.00
Averages
51.75
High
65.00
About PRCT
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PROCEPT BioRobotics Outlines 2026 Financial Targets
- 2026 Financial Outlook: PROCEPT expects revenue between $390 million and $410 million in 2026, reflecting a growth rate of 27% to 33%, with a target of 60,000 to 64,000 procedures and a gross margin of 65%, while adjusted EBITDA loss is projected between $30 million and $17 million, with a positive EBITDA expected in Q4, indicating a strong shift towards profitability.
- Market Opportunity and Strategy: CEO Larry Wood highlighted that approximately 400,000 patients undergo prostate procedures annually, with Aquablation penetration at only 10%, indicating a significant untapped market in benign prostatic hyperplasia (BPH) and prostate cancer treatment, which could drive future growth through increased market share.
- Pricing and Sales Strategy Adjustments: PROCEPT has eliminated quarter-end discounting to reduce revenue volatility and enhance average selling prices (ASP), projecting that handpiece ASP will rise to about $3,500 by 2026, a change that is expected to improve margins and support the company's path to profitability.
- Clinical Trial Progress: The ongoing WATER IV trial, involving 280 patients, is on track to present results at the AUA in 2027, and strong data could significantly expand the addressable market, further solidifying the company's strategic positioning in prostate cancer treatment.
See More
US Stocks Close Mixed: Dow Rises Slightly, Nasdaq Declines
- Mixed Market Performance: On Thursday, the S&P 500 Index fell by 0.54% and the Nasdaq 100 Index declined by 1.16%, while the Dow Jones Industrial Average rose slightly by 0.03%, indicating a divergence in market sentiment, particularly under pressure from tech stocks.
- Nvidia Earnings Impact: Nvidia reported Q4 revenue of $62.3 billion, exceeding expectations, yet its stock dropped over 5% due to uncertainties regarding the Chinese market, reflecting investor concerns about an overheated AI economy that could affect related chipmakers' performance.
- Labor Market Signals: Initial jobless claims in the US rose by 4,000 to 212,000, lower than the expected 216,000, indicating resilience in the labor market, which may provide support for the stock market, especially amid potential interest rate cuts by the Fed.
- Geopolitical Risks Intensify: President Trump threatened military action against Iran, heightening market uncertainty; although there are signs of progress in US-Iran nuclear negotiations, geopolitical risks remain a focal point for investors and could negatively impact the stock market.
See More
PROCEPT BioRobotics Under Investigation for Securities Fraud
- Investigation Background: Ademi LLP is investigating possible securities fraud claims against PROCEPT BioRobotics, focusing on potentially false statements regarding the company's financial statements, business operations, and prospects, which could lead to significant investor losses.
- Sales Data Distortion: The investigation centers on whether PROCEPT BioRobotics accurately disclosed its sales processes and inventory for disposable handpieces, as a significant portion of sales relied on quarter-end promotional discounts that the company has now discontinued.
- Performance Warning: As a result of halting promotional discounts, PROCEPT BioRobotics reported quarterly revenue 19% below forecasts, and its annual sales guidance for 2026 is also 5% below expectations, which may undermine market confidence and affect stock performance.
- Legal Consequences: This investigation could lead to securities fraud litigation, prompting investors to monitor developments closely to assess the potential impact on the company's future financial health and shareholder interests.
See More
PROCEPT BioRobotics Under Investigation for Securities Fraud Claims
- Investigation Background: Ademi LLP is investigating potential securities fraud claims against PROCEPT BioRobotics due to possibly inaccurate statements regarding its financial statements, business operations, and prospects, which could lead to investor losses.
- Sales Disclosure Issues: The investigation focuses on whether PROCEPT BioRobotics' disclosures regarding the sales processes and inventory of its disposable handpieces were accurate, particularly as these sales relied on quarter-end promotional discounts that have since been discontinued.
- Financial Forecast Downgrade: As a result of the reliance on discontinued promotional discounts, PROCEPT BioRobotics reported quarterly revenue 19% below forecasts, and its annual sales guidance for 2026 is also 5% below expectations, potentially undermining market confidence in the company.
- Potential Legal Consequences: This investigation could lead to securities fraud litigation, and if wrongdoing is confirmed, it may severely impact the company's stock price and reputation, prompting investors to closely monitor further developments.
See More
US Stocks Mostly Lower as Nvidia Earnings Fail to Boost Market Sentiment
- Market Weakness: The S&P 500 index fell by 0.74% and the Nasdaq 100 index dropped by 1.40%, indicating market concerns over Nvidia's earnings failing to alleviate worries about an overheated AI economy, which pressured chipmakers and AI infrastructure stocks.
- Nvidia Earnings Impact: Despite Nvidia reporting Q4 revenue of $62.3 billion, surpassing the consensus of $60.36 billion, its stock declined over 4% due to concerns regarding the Chinese market, reflecting investor doubts about demand durability.
- Salesforce Strong Performance: Salesforce shares rose more than 3%, leading software stocks higher after it provided a strong long-term sales outlook and announced a large share buyback, alleviating fears of AI disruption in the software sector.
- Geopolitical Risks Intensify: Ongoing nuclear talks between the US and Iran have heightened geopolitical risks, with President Trump threatening military action against Iran, which has further impacted investor sentiment and market stability.
See More
PROCEPT BioRobotics Q4 2025 Earnings Call Insights
- Revenue Growth: PROCEPT BioRobotics reported total revenue of $76.4 million for Q4 2025, reflecting a 12% year-over-year increase, with U.S. revenue at $66.6 million and a notable 69% growth in procedures, although gross margin decreased to 60.6% due to a one-time field action.
- Organizational Restructuring: CEO Larry Wood emphasized the realignment of the commercial team into an integrated regional structure and the establishment of a dedicated launch team, which aims to ensure that clinical and commercial activities are coordinated around customer success and procedure growth, thereby enhancing market share and profitability.
- Future Outlook: The company expects total revenue for 2026 to range between $390 million and $410 million, with anticipated growth of 27% to 33%, and projects U.S. procedures to reach between 60,000 and 64,000, indicating strong confidence in future market performance.
- Cost and Expenses: Operating expenses for 2026 are expected to reach $350 million, a 17% increase, while adjusted EBITDA loss is projected to be between $30 million and $17 million, although management anticipates achieving positive EBITDA in Q4 2026.
See More
PROCEPT BioRobotics Outlines 2026 Financial Targets
- 2026 Financial Outlook: PROCEPT expects revenue between $390 million and $410 million in 2026, reflecting a growth rate of 27% to 33%, with a target of 60,000 to 64,000 procedures and a gross margin of 65%, while adjusted EBITDA loss is projected between $30 million and $17 million, with a positive EBITDA expected in Q4, indicating a strong shift towards profitability.
- Market Opportunity and Strategy: CEO Larry Wood highlighted that approximately 400,000 patients undergo prostate procedures annually, with Aquablation penetration at only 10%, indicating a significant untapped market in benign prostatic hyperplasia (BPH) and prostate cancer treatment, which could drive future growth through increased market share.
- Pricing and Sales Strategy Adjustments: PROCEPT has eliminated quarter-end discounting to reduce revenue volatility and enhance average selling prices (ASP), projecting that handpiece ASP will rise to about $3,500 by 2026, a change that is expected to improve margins and support the company's path to profitability.
- Clinical Trial Progress: The ongoing WATER IV trial, involving 280 patients, is on track to present results at the AUA in 2027, and strong data could significantly expand the addressable market, further solidifying the company's strategic positioning in prostate cancer treatment.
See More
US Stocks Close Mixed: Dow Rises Slightly, Nasdaq Declines
- Mixed Market Performance: On Thursday, the S&P 500 Index fell by 0.54% and the Nasdaq 100 Index declined by 1.16%, while the Dow Jones Industrial Average rose slightly by 0.03%, indicating a divergence in market sentiment, particularly under pressure from tech stocks.
- Nvidia Earnings Impact: Nvidia reported Q4 revenue of $62.3 billion, exceeding expectations, yet its stock dropped over 5% due to uncertainties regarding the Chinese market, reflecting investor concerns about an overheated AI economy that could affect related chipmakers' performance.
- Labor Market Signals: Initial jobless claims in the US rose by 4,000 to 212,000, lower than the expected 216,000, indicating resilience in the labor market, which may provide support for the stock market, especially amid potential interest rate cuts by the Fed.
- Geopolitical Risks Intensify: President Trump threatened military action against Iran, heightening market uncertainty; although there are signs of progress in US-Iran nuclear negotiations, geopolitical risks remain a focal point for investors and could negatively impact the stock market.
See More
PROCEPT BioRobotics Under Investigation for Securities Fraud
- Investigation Background: Ademi LLP is investigating possible securities fraud claims against PROCEPT BioRobotics, focusing on potentially false statements regarding the company's financial statements, business operations, and prospects, which could lead to significant investor losses.
- Sales Data Distortion: The investigation centers on whether PROCEPT BioRobotics accurately disclosed its sales processes and inventory for disposable handpieces, as a significant portion of sales relied on quarter-end promotional discounts that the company has now discontinued.
- Performance Warning: As a result of halting promotional discounts, PROCEPT BioRobotics reported quarterly revenue 19% below forecasts, and its annual sales guidance for 2026 is also 5% below expectations, which may undermine market confidence and affect stock performance.
- Legal Consequences: This investigation could lead to securities fraud litigation, prompting investors to monitor developments closely to assess the potential impact on the company's future financial health and shareholder interests.
See More
PROCEPT BioRobotics Under Investigation for Securities Fraud Claims
- Investigation Background: Ademi LLP is investigating potential securities fraud claims against PROCEPT BioRobotics due to possibly inaccurate statements regarding its financial statements, business operations, and prospects, which could lead to investor losses.
- Sales Disclosure Issues: The investigation focuses on whether PROCEPT BioRobotics' disclosures regarding the sales processes and inventory of its disposable handpieces were accurate, particularly as these sales relied on quarter-end promotional discounts that have since been discontinued.
- Financial Forecast Downgrade: As a result of the reliance on discontinued promotional discounts, PROCEPT BioRobotics reported quarterly revenue 19% below forecasts, and its annual sales guidance for 2026 is also 5% below expectations, potentially undermining market confidence in the company.
- Potential Legal Consequences: This investigation could lead to securities fraud litigation, and if wrongdoing is confirmed, it may severely impact the company's stock price and reputation, prompting investors to closely monitor further developments.
See More
US Stocks Mostly Lower as Nvidia Earnings Fail to Boost Market Sentiment
- Market Weakness: The S&P 500 index fell by 0.74% and the Nasdaq 100 index dropped by 1.40%, indicating market concerns over Nvidia's earnings failing to alleviate worries about an overheated AI economy, which pressured chipmakers and AI infrastructure stocks.
- Nvidia Earnings Impact: Despite Nvidia reporting Q4 revenue of $62.3 billion, surpassing the consensus of $60.36 billion, its stock declined over 4% due to concerns regarding the Chinese market, reflecting investor doubts about demand durability.
- Salesforce Strong Performance: Salesforce shares rose more than 3%, leading software stocks higher after it provided a strong long-term sales outlook and announced a large share buyback, alleviating fears of AI disruption in the software sector.
- Geopolitical Risks Intensify: Ongoing nuclear talks between the US and Iran have heightened geopolitical risks, with President Trump threatening military action against Iran, which has further impacted investor sentiment and market stability.
See More
PROCEPT BioRobotics Q4 2025 Earnings Call Insights
- Revenue Growth: PROCEPT BioRobotics reported total revenue of $76.4 million for Q4 2025, reflecting a 12% year-over-year increase, with U.S. revenue at $66.6 million and a notable 69% growth in procedures, although gross margin decreased to 60.6% due to a one-time field action.
- Organizational Restructuring: CEO Larry Wood emphasized the realignment of the commercial team into an integrated regional structure and the establishment of a dedicated launch team, which aims to ensure that clinical and commercial activities are coordinated around customer success and procedure growth, thereby enhancing market share and profitability.
- Future Outlook: The company expects total revenue for 2026 to range between $390 million and $410 million, with anticipated growth of 27% to 33%, and projects U.S. procedures to reach between 60,000 and 64,000, indicating strong confidence in future market performance.
- Cost and Expenses: Operating expenses for 2026 are expected to reach $350 million, a 17% increase, while adjusted EBITDA loss is projected to be between $30 million and $17 million, although management anticipates achieving positive EBITDA in Q4 2026.
See More
